This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

5 Short Squeeze Stocks Ready to Pop in October

Gilead Sciences

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

2013 has been a blockbuster year for Gilead Sciences ( GILD) -- shares of the $96 billion biopharmaceutical company have charged more than 70% higher since the start of the year. But that upward momentum hasn't kept short sellers at bay; it's only made them shout their value argument louder. As I write, GILD carries a short interest ratio of 10.01, indicating that it would take more than two weeks of buying pressure for short sellers to exit their bets against this stock.

>>4 Biotech Stocks Under $10 Making Big Moves

Gilead's business centers around creating and marketing drugs that fight infectious diseases, with a focus on HIV and hepatitis B and C. Gilead's HIV treatments are making waves in the health care field -- the all-in-one pill Atripla dramatically simplifies the daily regimen for HIV patients, for instance. The firm also made an $11 billion bet on treating hepatitis C through the acquisition of drug maker Pharmasset. That diversification should be welcome for investors in this concentrated stock.

While patent expirations are a concern for Gilead, the firm's keystone HIV patents don't start expiring until 2018, ample time for the firm to develop new formulations and to keep adding other diseases to its hit list. Financially, GILD is in solid shape in spite of its transformational acquisition efforts, with $3 billion in cash and investments largely offsetting a $7.3 billion debt load.

There's no question that Gilead isn't exactly cheap right now, but it's trajectory isn't showing any signs of slowing either.

2 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,234.72 +77.87 0.45%
S&P 500 2,010.44 +8.87 0.44%
NASDAQ 4,588.0670 +25.8780 0.57%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs